Research Paper

MYC dysfunction modulates stemness and tumorigenesis in breast cancer

Yiqiu Liu1#, Chengjun Zhu1#, Lin Tang2, Qin Chen3, Nan Guan3, Kun Xu1, Xiaoxiang Guan1**

1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
2. Department of Medical Oncology, Medical School of Nanjing University, Nanjing, 210002, China.
3. College of Letters and Science, University of California, Los Angeles, 405 Hilgard Avenue, California, 90095, USA.

#These authors contributed equally to this study.

**Corresponding author: Xiaoxiang Guan, E-mail: xguan@njmu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Abstract

As a transcription factor and proto-oncogene, MYC is known to be deregulated in a variety of tumors, including breast cancer. However, no consistent conclusion on the role and mechanism of MYC deregulation during breast cancer carcinogenesis has been formed. Here, we used the UALCAN, bc-GenExMiner, TCGA, cBioportal, STRING and Kaplan-Meier Plotter databases to explore the mRNA expression, prognosis, transcriptional profile changes, signal pathway rewiring and interaction with the cancer stem cells of MYC in breast cancer. We found that the expression of MYC varies in different subtypes of breast cancer, with relatively high frequency in TNBC. As a transcription factor, MYC not only participates in the rewiring of cancer signaling pathways, such as estrogen, WNT, NOTCH and other pathways, but also interacts with cancer stem cells. MYC is significantly positively correlated with breast cancer stem cell markers such as CD44, CD24, and ALDH1. Collectively, our results highlight that MYC plays an important regulatory role in the occurrence of breast cancer, and its amplification can be used as a predictor of diagnosis and prognosis. The interaction between MYC and cancer stem cells may play a crucial role in regulating the initiation and metastasis of breast cancer.

Key words: MYC, cancer stem cells, breast cancer, tumorigenesis

Introduction

Based on the latest statistics from the American Cancer Society and the National Cancer Institute, breast cancer, with the highest prevalence and mortality, accounts for approximately 44% of all cancers among female [1]. Despite the yearly increase in incidence, the five-year survival rate of breast cancer has improved from 79% in 1986 to 91% in 2014, excluding triple-negative breast cancer (TNBC) whose 5-year survival rate ranks lowest [2]. Nevertheless, the gradually decreasing medium age of diagnosis and the increasing ratio of tumor metastasis among survivors with relatively limited treatment measures, including radiotherapy, chemotherapy and surgery, all demonstrate the fact that breast cancer is still an arduous challenge for researchers and patients, highlighting the urgency of discovering new diagnostic biomarkers and therapeutic targets [1, 3].

MYC is a transcription factor whose family includes c-myc, B-myc, L-myc, N-myc and s-myc [4, 5]. Highly conserved in evolution, MYC preserves the N-terminal domain (NTD) containing MB1, MB2 for gene transcription regulation and the C-terminal domain (CTD) holding basic helix-loop-helix leucine zipper transcription factors (bHLHLZ) for DNA binding and heterodimerization [4]. Acting as a transcription regulator, MYC works with other transcription factors and target genes to regulate many life events like cell growth, apoptosis, metabolism and tumorigenesis [4, 6]. Many studies have proven that MYC is a proto-oncogene which has been found deregulated in many cancers including Burkitt’s lymphomas, lung carcinoma, breast carcinoma, and colon carcinoma [7-10].

Previous studies have found that MYC is deregulated in 30%-50% of the high-grade breast cancers, whose tumorigenic ability is also confirmed.
by the MMTV-c-myc/WAP-c-myc transgenic mice [11-14]. Notwithstanding all these phenomena we have found, the exact process by which MYC interacts with other genes promoting tumorigenesis remains unknown. Herein, by using online databases, we explored the expression changes, prognosis value, interacting genes, especially the cancer stem cell biomarkers, and the altered signal pathways of MYC during breast cancer tumorigenesis, hoping to shed light on the new biomarkers and therapeutic targets for breast cancer.

**Materials and Methods**

**Differential mRNA expression of MYC and its relationship with prognosis**

We used ONCOMINE (http://www.oncomine.org), UALCAN (http://ualcan.path.uab.edu), bc-GenExMiner (http://bcgenex.ico.unicancer.fr) and Kaplan-Meier plotter (http://kmplot.com/analysis/) databases to explore the differential mRNA expression of MYC and its relationship with prognosis [61-62]. Firstly, we used UALCAN databases to observe the pan-cancer analysis of MYC mRNA expression. Secondly, we used UALCAN and bc-GenExMiner database to explore the differential mRNA expression of MYC in breast cancer subtypes and TNBC subtypes. Finally, Kaplan-Meier plotter was utilized to analyze the interrelation of relapse-free survival (RFS) curves of breast cancer patients with high and low expression of MYC.

**Gene alterations and transcriptional regulations of MYC**

We used cBioportal (https://www.cbioportal.org), TRRUST (https://www.grnpedia.org/trrust/) and STRING (https://string-db.org) databases to explore the gene alterations and transcriptional regulations of MYC in breast cancer patients[63-65]. In order to obtain the gene alterations in cBioportal, firstly, we used the Breast Invasive Carcinoma (TCGA, PanCancer Atlas) database, then we selected the genomic profiles as Mutations, Putative copy-number alterations from GISTIC, and mRNA expression z-scores relative to all samples (log RNA Seq V2 RSEM). Patient/case set was selected as all samples, and MYC was entered to get the proportion and type of genetic alterations of MYC in breast cancer patients and breast cancer subclasses. To acquire the transcriptional regulations of MYC, we used TRRUST database to get the MYC target genes and transcription factors regulating MYC. Afterwards, data obtained from TRRUST were inputted into the STRING database to obtain the protein interaction network of MYC with its upstream transcription factors and downstream target genes.

**The alternations of signal pathway of MYC and its relationship with cancer stem cells**

We used KEGG (https://www.genome.jp/kegg/), TCGA (https://portal.gdc.cancer.gov/), TRRUST (https://www.grnpedia.org/trtrust/) and STRING (https://string-db.org) databases to explore the changes of MYC pathway and its relationship with breast cancer stem cells. Firstly, in the KEGG PATHWAY, keyword was entered as c-myc and the name was selected as breast cancer to achieve the pathway alteration map of MYC in breast cancer patients. Secondly, the correlation between MYC and the classic breast cancer stem cells (BCSCs) was analyzed in TCGA database by Pearson’s correlation. Then, STRING database was applied to obtain the protein interaction network between MYC and BCSCs. Finally, TRRUST and STRING databases were used to verify the crosstalk between MYC-related transcription factors and classical BCSCs.

**Clinical drug trials involving MYC in breast cancer patients**

We utilized the ClinicalTrials (https://clinicaltrials.gov/) database to obtain the clinical drug trial data related to MYC. In ClinicalTrials Database, the status was set as all studies, condition or disease was set as breast cancer, and other terms was set as MYC to obtain the MYC-related clinical drug research data.

**Results**

**Interrelation of the changes of the expression of MYC mRNA with the clinicopathological parameters and the clinical prognosis of the breast cancer patients**

To get an overall idea of the expression of MYC in all tissues and its association with the clinicopathological parameters of the breast cancer patients, we applied UALCAN (http://ualcan.path.uab.edu) and bc-GenExMiner (http://bcgenex.ico.unicancer.fr) databases. According to Figure 1A and 1B, we found that compared with normal breast tissues, the expression of the mRNA of MYC in tumor tissues was decreased except the basal-like subtype. As was depicted in Figure 1B and 1D, there were significant differences in the expression of MYC among different subtypes of breast cancer, and the expression of MYC was relatively high in TNBC. Furthermore, in the case of the TNBC subclasses, MYC was associated with TNBC-LAR, TNBC-MSL, TNBC-UNS, TNBC-BL2, but showed no statistical difference with TNBC-BL1, TNBC-M, TNBC-IM (Figure 1C). We obtained the prognosis of breast cancer patients corresponding to
the expression of MYC by using KMPlot (http://kmplot.cm/analysis) database. As was illustrated in Figure 1E, there was a significant correlation between the expression of MYC and RFS in patients with breast cancer. Nonetheless, the unit that MYC exercises its function is protein. Because of the lack of databases about the relationship between the protein and patient prognosis currently, the association between MYC expression and patient prognosis requires further studies to confirm.

Molecular mechanisms of the abnormal functions of MYC during breast cancer tumorigenesis

Gene alterations of MYC in patients with breast cancer

In order to explore the gene structure and transcriptional changes of MYC, we used cBioportal (https://www.cbioportal.org), TRRUST (https://www.grnpedia.org/trrust/) and STRING (https://string-db.org) databases. As to what genetic changes have taken place in MYC, according to Figure 2A-2B, the MYC gene was altered in 19% of the patients and amplification was the predominant form of MYC gene alterations in breast cancer. Among the different subtypes of breast cancer, as described in Figure 2B, Breast Invasive Ductal Carcinoma had the highest mutation frequency of MYC, followed by Breast Invasive Mixed Mucinous Carcinoma and Breast Invasive Carcinoma (NOS), whereas Breast Invasive Lobular Carcinoma had the lowest mutation frequency of MYC. In all breast cancer subtypes, however, amplification was the leading form of mutation, accounting for 1/2-3/4 of the frequency. According to our previous data[15], the frequency of

Figure 1. The expression of MYC and its association with the clinical prognosis of breast cancer patients. (A) The pan-cancer analysis showing the differential expression of MYC in UALCAN database. (B) The Box plot depicting the MYC expression analysis according to Sorlie’s subtypes in bc-GenExMiner database. (C) and (D) The Box plots depicting the MYC expression analysis according to TNBC subtypes and breast cancer subclasses, respectively, in UALCAN database. *P<0.05, **P<0.01, ***P<0.001. (E) The Kaplan-Meier survival curve of RFS based on MYC expression in breast cancer patients in Kaplan-Meier plotter database (log-rank test, p<0.01).
gene alterations of MYC in breast cancer patients was 37.3% from ctDNA and 17.6% from breast cancer tissues (Figure 2C), which was consistent with the results of the database. In order to unveil the transcriptional profile of MYC, we used TRRUST and STRING database to discover the changes in MYC-related transcription factors and obtain the protein interaction network. Protein interaction networks concerning the MYC target genes and the transcription factors regulating MYC were shown in Figure 2D-2E, from which we could find that MYC target genes are closely related to the cell cycle, for example, CDC25C and CDK4/6, and accordingly we could speculate that MYC might be an essential transcription factor regulating the cell growth and proliferation and other life processes. Among the transcription factors regulating MYC, there are many star signal pathway factors, such as SMAD and STAT, which indicates that MYC might also function as an important signal transduction factor.

Pathways rewiring of MYC during tumorigenesis

The tumorigenesis can be interpreted as the consequence of an imbalance of the expression of signal pathways. MYC is an important downstream regulator of the signal pathway, so understanding the rewiring pathway of MYC is critical to understand the occurrence of breast cancer. As was shown in Figure 3A, we obtained the signaling pathway changes that MYC participates in among breast cancer subclasses by KEGG database (https://www.genome.jp/kegg/). Based on the figure, we could observe that Luminal A and Luminal B were closely related to hormone-related pathways such as estrogen/progesterone signaling pathway. In addition, basal-like breast cancer was markedly associated with two star signaling pathways of Notch and Wnt. From the chart, we could also ascertain that MYC was dominantly involved in DNA damage repair and cell cycle-related pathways. We could also infer from the figure that MYC did not regulate transcription alone, but interacted with many oncogenes like FGFR1 and PI3KCA and tumor suppressor genes such as p53, PTEN and BRCA1/2 to regulate tumorigenesis, and interacted with many regulatory factors to regulate many essential physiological activities.

Figure 2. The genetic alterations and transcriptional regulation of MYC in breast cancer patients. (A) and (B) Schematic diagrams depicting the proportion and type of genetic alterations of MYC in breast cancer patients and breast cancer subclasses, respectively, in cBioportal database. (C) Sequencing results showing the proportion and type of genetic alterations of MYC in ctDNAs and tissues of breast cancer patients. (D and E) Protein interaction networks showing the transcription factors regulating MYC and MYC downstream target genes respectively, in STRING database.
In order to further explore the pathway changes of MYC in breast cancer, we applied the MYC transcriptional regulation profile obtained from TRRUST (https://www.grnpedia.org/trrust) database and inputted it into STRING (https://string-db.org) database. Under the restriction conditions of breast cancer and pathways in cancer, we achieved Figure 3B-3C, which displayed the MYC target genes and transcription factors regulating MYC involved in the breast cancer signaling pathway rewiring.

From Figure 3B-3C, we could find that FOS, JUN, E2F1, RB1, ESR1, SPI, APC, LEF1 and CTNNB1 were found in the transcription factors regulating MYC, MAPK1, KRAS, CDKN1A, CDK4/6 and CCND1 were found in the MYC target genes of MYC, and TP53 was present in both the downstream target genes and upstream transcription factors of MYC. All these can provide further clues for the follow-up study of the specific role of MYC in breast cancer pathway remodeling.

Correlation between MYC and breast cancer stem cells

A special subgroup of tumor cells, also acknowledged as cancer stem cells (CSCs), can renew itself, as well as promote tumor metastasis, EMT, recurrence and drug resistance [16-20]. Because of the heterogeneity, constant dynamic changes, and noteworthy correlation with the shorter OS, DFS in cancer patients, cancer stem cells play an essential role in tumorigenesis [17,18]. Here, we use TCGA, STRING database to explore the relationship between MYC and breast cancer stem cells.
According to Figure 4A, MYC was significantly correlated with the classic biomarkers of breast cancer stem cells such as CD44, CD133, CD29, ALDH and EPCAM, but not with CD24, and the protein interaction network between MYC and the biomarkers was depicted in Figure 4B. In order to further verify the relationship between MYC and breast cancer stem cells, we used STRING database, where the KEGG pathways option of analysis section was set to be breast cancer and signaling pathways regulating pluripotency of stem cells, and we found that there is a significant intersection between MYC and the upstream and downstream transcriptional regulators (Figure 4C-D). All these suggested that MYC may regulate the initiation and differentiation of cancer stem cells and therefore, affect the initiation, proliferation and metastasis of breast cancer.

**Advances in the treatment related to MYC**

As MYC functions as an essential role in promoting tumorigenesis, targeted therapy for MYC has always been a research hotspot. Currently, the treatment of MYC is divided into direct treatment and indirect treatment [21-24]. Direct therapy refers to the therapy directly binding to MYC by interfering with its promoter, the recruitment of transcription factors, and the ability to directly bind to other proteins, such as MAX. Among them, the representative drugs are AVI-4126, 10058-F4, Omomyc and so on. Because of the deficiency of an ordered internal structure and a binding capsule of MYC in direct therapy, at present, the researches on MYC treatment are mainly focusing on indirect treatment. Indirect therapy refers to the therapy regulating MYC transcription, translation, stability and synthetic lethality without directly binding to MYC, such as JQ1, P22077, MK2206, and so on [25-33]. Pivotal regulatory factors of MYC in these processes and their targeted drugs are summarized in Figure 5. Clinical trials involving MYC in breast cancer patients are summarized in Table 1 using ClinicalTrials database (https://clinicaltrials.gov/).
Table 1. Clinical drug trials involving MYC in breast cancer patients

| Trial number | Trial phase | Patients | Interventions | Status       |
|--------------|-------------|----------|---------------|--------------|
| NCT00898898  | Not Applicable | Primary HER2 positive breast cancer | Other: diagnostic laboratory biomarker analysis | Completed     |
| NCT01676753  | Phase I      | Advanced or Metastatic Breast Cancer; Triple Negative Breast Cancer. | Drugs: Dinaciclib; Pembrolizumab | Active, not recruiting |
| NCT00740532  | Not Applicable | Metastatic Breast Cancer | Genetic: Gene mutation analyses and FISH | Completed     |
| NCT01534455  | Phase II     | Metastatic Breast Cancer | Drugs: Lapatinib + 1.23 mg Eribulin; Lapatinib + 1.76 mg Eribulin | Terminated    |
| NCT00740532  | Not Applicable | Metastatic Breast Cancer | Drug: Paclitaxel | Recruiting    |
| NCT01346570  | Phase III    | Early Breast Cancer | Biological: trastuzumab; Drug: lapatinib ditosylate; Other: laboratory biomarker analysis; Procedures: adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery. | Active, not recruiting |
| NCT03085368  | Phases II & III | HER2-positive Breast Cancer | Drug: lapatinib/trastuzumab | Recruiting    |
| NCT00553358  | Phase III    | HER2/Erbb2 Positive Primary Breast Cancer | Drug: Lapatinib; Biological: Trastuzumab; Drug: Paclitaxel. | The pCR rate was significantly higher in the group given lapatinib and trastuzumab. No significant difference in pCR between the lapatinib and the trastuzumab groups [66]. |

Discussion

Conclusively, online database was used to elucidate the alterations of MYC mRNA expression, the relationship between MYC expression and prognosis, the mechanism of MYC deregulation in tumorigenesis and the progress of treatment in breast cancer patients. It was found that the mRNA expression of MYC was decreased in breast cancer patients, which was related to breast cancer subclasses and TNBC subtypes. Moreover, it is the amplification neither mRNA expression nor mutations, that accounted for most alterations of MYC during breast cancer tumorigenesis. Previous studies and our group’s sequencing data showed that the amplification rate of MYC in breast cancer patients was approximately 16%-20% [15, 34-36]. We also found that the expression of MYC is related to the RFS
of breast cancer patients, but the lack of follow-up data of large samples of patients indicates that further large-scale investigation is needed. MYC participated in the vital signal pathway rewiring, including NOTCH, WNT, estrogen and MAPK pathways.

As a transcription factor and proto-oncogene, MYC can not only activate but also inhibit transcription [4, 37]. MYC binds to MAX as a heterodimer, recognizing the E-box on the target gene, usually 5'-CACGTG-3' [6, 38-41], and transcription is activated by histone acetylation, chromatin recombination and promoter clearance, and can also be inhibited by identifying the Inr sequence on the target gene [41]. MYC regulates a series of processes such as cell cycle, metabolism, apoptosis, and so on. For example, MYC can bind to transcription factors such as TPPAP, CBP and P300 to stimulate acetylation [42, 43], p-TEFb, TFIIH and pol II/III to activate transcription [44], ARP, p53 and caspase 9 to stimulate apoptosis [6, 45]. It’s the target genes bound by MYC that determine the cellular functions and biological activities.

Recent studies have concentrated on the role and mechanism by which MYC interacts with cancer stem cells. MYC can delay self-degradation by combining with p62, or form a loop with FGF13-AS1 and IGFBP-6 and other factors [46]. Chang et al. found that MYC interacts with the cancer-associated fibroblasts (CAFs) in the microenvironment participating in the tumor initiation through IGF, IGFBP-6 and other factors [46]. Chang et al. found that MYC promotes tumorigenesis by blocking the PI3K/Akt/β-Catenin pathway through the regulation of Slit2/Robo1 [47]. Recent studies have shown that MYC interacts with macrophages and fibroblasts in the microenvironment to promote tumor brain metastasis and drug resistance by regulating factors such as BrMs, GJA1/Cx43, LIN28B, miR-34a-5p, and so on [20, 48].

MYC is closely correlated with tumorigenesis, such as proliferation, transformation, metastasis, and drug resistance. It regulates cyclin D1, cyclin A, cyclin E and cdc25A which can phosphorylate CDK2/4 [6, 49-52], and moreover, it can inhibit p27 and other CKIs [53, 54], collectively modulating DNA synthesis and genomic instability to promote proliferation. MYC can bind to genes related to cell differentiation, such as C/EBP, AP-2 [55, 56], and by identifying the internal Inr sequence of these genes which inhibit transcription it can hinder differentiation and promote cell transformation [6, 57]. MYC can additionally act as a bridge between cancer stem cell-like properties and metastasis. MYC increases breast cancer stem cell-like properties and EMT by binding to DOT1L and p300, which stimulates SNAIL, ZEB1, ZEB2 transcription and promotes lysine-79 methylation and H3 acetylation through gene epigenetic modification [58]. MYC can further enhance the drug resistance by changing tumor cell metabolism which increases glutaminyls and glycolysis [14, 59, 60]. Due to the limitation of the sample size of previous studies and lack of follow-up data, the application prospect of MYC as a diagnostic biomarker and prognostic indicator of breast cancer has yet to be further examined. Presently, the therapies targeted MYC are divided into direct and indirect. Due to the shortcomings of the complex internal structure and lack of the binding capsule of MYC, currently, most studies are focusing on the key regulatory factors manipulating the deregulated expression of MYC and the combined therapy with other proto-oncogenes [21-24]. More studies should focus on the relationship between MYC amplification frequency and prognosis in large samples of patients, the efficacy of MYC combined targeted therapy and the alterations of specific signal pathway of MYC in the process of breast cancer tumorigenesis.

In conclusion, the differential expression, transcriptional profile, involvement in the cancer pathways alterations, and the interaction with cancer stem cells provide a new idea for targeted molecular therapy of MYC in breast cancer patients and provide clues and directions for a better understanding of the molecular mechanism of breast cancer tumorigenesis.

Acknowledgements

This research was supported by Key International Cooperation of National Natural Science Foundation of China (No. 81920108029) (to X.G.).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Miller KD, Negri L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA: a cancer journal for clinicians. 2019; 69: 363-85.
2. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. Based on the November 2017 SEER data submission. Bethesda, MD: National Cancer Institute, 2018. seer.cancer.gov/csr/1975_2015/. Accessed May 7, 2019.
3. American College of Surgeons Commission on Cancer. National Cancer Database, 2016 Data Submission. Chicago, IL: American College of Surgeons Commission on Cancer. 2019.
26. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, et al. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer. BioDrugs: clinical immunotherapeutics, molecular, cellular and developmental biology. 2016; 38: 266-75.

27. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nature. 2006; 17: 563-75.

28. Allen-Petersen BL, Sears RC. Stabilization of N-Myc is a critical function of Aurora A in human primary breast cancer. Proc Natl Acad Sci U S A. 1986; 83: 4833-8.

29. Deming SL, Nasser SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. British journal of cancer. 2000; 83: 1017-22.

30. Jaenicke LA, von Eys, Carstensen A, Wolf E, Xu W, Greifenberg AK, et al. Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Formation to Drive Transcriptional Elongation. Molecular cell. 2016; 61: 1769-75.

31. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTMV/myc fusion genes. Cell. 1984; 36: 257-67.

32. Schoenenerger CA, Andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein secretion. The EMBO journal. 1989; 8: 2397-404.

33. Sandgren EP, Jongboom JA, Palmiter RD, Brinster RL, Lee DC. Hybrid gene transcription by myc proteins to canonical and noncanonical DNA sequences. Molecular and cellular biology. 1993; 13: 5216-24.

34. Jamerson MH, Johnson MD, Dickson RB. Of mice and Myc: c-Myc and bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146: 904-17.

35. Rusnak K, Tofigh S, Feng J, Slamon DJ. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast cancers. Nat Genet. 1993; 5: 56-61.

36. Deming SL, Nasser SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. British journal of cancer. 2000; 83: 1017-22.
58. Cho MH, Park JH, Choi HJ, Park MK, Won HY, Park YJ, et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nature communications. 2015; 6: 7821.

59. Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, et al. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Molecular cancer. 2014; 13: 239.

60. Chen Z, Wang Y, Warden C, Chen S. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. The Journal of steroid biochemistry and molecular biology. 2015; 149: 118-27.

61. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19: 649-58.

62. Nagy Á, Lánzczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Scientific reports. 2018; 8: 9227.

63. Szklarczyk D, Gable AL, Lydon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research. 2019; 47: D607-D13.

64. Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic acids research. 2017; 45: D362-D8.

65. Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic acids research. 2018; 46: D380-D6.

66. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379: 633-40.